Atara Biotherapeutics (ATRA) Competitors $8.01 -0.24 (-2.91%) Closing price 07/3/2025 03:37 PM EasternExtended Trading$8.32 +0.31 (+3.86%) As of 07/3/2025 04:01 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock ATRA vs. ORIC, DRUG, CTMX, OGI, PROK, VYGR, FDMT, PBYI, IPHA, and DMACShould you be buying Atara Biotherapeutics stock or one of its competitors? The main competitors of Atara Biotherapeutics include Oric Pharmaceuticals (ORIC), Bright Minds Biosciences (DRUG), CytomX Therapeutics (CTMX), Organigram Global (OGI), ProKidney (PROK), Voyager Therapeutics (VYGR), 4D Molecular Therapeutics (FDMT), Puma Biotechnology (PBYI), Innate Pharma (IPHA), and DiaMedica Therapeutics (DMAC). These companies are all part of the "pharmaceutical products" industry. Atara Biotherapeutics vs. Its Competitors Oric Pharmaceuticals Bright Minds Biosciences CytomX Therapeutics Organigram Global ProKidney Voyager Therapeutics 4D Molecular Therapeutics Puma Biotechnology Innate Pharma DiaMedica Therapeutics Oric Pharmaceuticals (NASDAQ:ORIC) and Atara Biotherapeutics (NASDAQ:ATRA) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their analyst recommendations, profitability, media sentiment, institutional ownership, risk, valuation, earnings and dividends. Is ORIC or ATRA more profitable? Oric Pharmaceuticals has a net margin of 0.00% compared to Atara Biotherapeutics' net margin of -7.83%. Atara Biotherapeutics' return on equity of 0.00% beat Oric Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets Oric PharmaceuticalsN/A -51.14% -46.29% Atara Biotherapeutics -7.83%N/A -14.51% Which has higher valuation & earnings, ORIC or ATRA? Atara Biotherapeutics has higher revenue and earnings than Oric Pharmaceuticals. Oric Pharmaceuticals is trading at a lower price-to-earnings ratio than Atara Biotherapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioOric PharmaceuticalsN/AN/A-$127.85M-$1.87-5.76Atara Biotherapeutics$199.73M0.24-$85.40M-$3.72-2.15 Which has more volatility & risk, ORIC or ATRA? Oric Pharmaceuticals has a beta of 1.54, meaning that its share price is 54% more volatile than the S&P 500. Comparatively, Atara Biotherapeutics has a beta of 0.18, meaning that its share price is 82% less volatile than the S&P 500. Do analysts rate ORIC or ATRA? Oric Pharmaceuticals presently has a consensus target price of $19.17, suggesting a potential upside of 77.96%. Atara Biotherapeutics has a consensus target price of $17.75, suggesting a potential upside of 121.60%. Given Atara Biotherapeutics' higher probable upside, analysts clearly believe Atara Biotherapeutics is more favorable than Oric Pharmaceuticals.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Oric Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 8 Buy rating(s) 0 Strong Buy rating(s) 3.00Atara Biotherapeutics 1 Sell rating(s) 2 Hold rating(s) 3 Buy rating(s) 1 Strong Buy rating(s) 2.57 Do institutionals & insiders have more ownership in ORIC or ATRA? 95.1% of Oric Pharmaceuticals shares are held by institutional investors. Comparatively, 70.9% of Atara Biotherapeutics shares are held by institutional investors. 6.8% of Oric Pharmaceuticals shares are held by insiders. Comparatively, 4.0% of Atara Biotherapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term. Does the media prefer ORIC or ATRA? In the previous week, Oric Pharmaceuticals had 4 more articles in the media than Atara Biotherapeutics. MarketBeat recorded 4 mentions for Oric Pharmaceuticals and 0 mentions for Atara Biotherapeutics. Oric Pharmaceuticals' average media sentiment score of 0.12 beat Atara Biotherapeutics' score of 0.00 indicating that Oric Pharmaceuticals is being referred to more favorably in the media. Company Overall Sentiment Oric Pharmaceuticals Neutral Atara Biotherapeutics Neutral SummaryOric Pharmaceuticals beats Atara Biotherapeutics on 9 of the 16 factors compared between the two stocks. Get Atara Biotherapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for ATRA and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding ATRA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ATRA vs. The Competition Export to ExcelMetricAtara BiotherapeuticsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$50.46M$2.89B$5.53B$9.04BDividend YieldN/A2.44%5.24%4.01%P/E Ratio-2.1521.7127.6420.25Price / Sales0.24281.12416.59118.23Price / CashN/A42.7336.8958.07Price / Book-0.477.518.035.67Net Income-$85.40M-$55.14M$3.18B$249.21M7 Day Performance0.63%4.61%2.92%3.28%1 Month Performance-4.87%4.72%3.72%5.55%1 Year Performance-3.26%5.92%35.14%21.08% Atara Biotherapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ATRAAtara Biotherapeutics4.1256 of 5 stars$8.01-2.9%$17.75+121.6%+3.9%$50.46M$199.73M-2.15330ORICOric Pharmaceuticals4.161 of 5 stars$10.15-1.6%$19.17+88.8%+43.2%$864.98MN/A-5.4380DRUGBright Minds Biosciences2.9164 of 5 stars$26.11+12.2%$83.25+218.8%+2,544.9%$183.81MN/A-72.53N/ANews CoverageAnalyst ForecastAnalyst RevisionCTMXCytomX Therapeutics4.0653 of 5 stars$2.27+0.9%$5.33+134.9%+91.5%$183.01M$147.56M4.73170OGIOrganigram Global0.6586 of 5 stars$1.35flatN/A-10.7%$180.82M$117.47M13.50860News CoveragePROKProKidney1.8169 of 5 stars$0.59-11.5%$3.50+491.1%-70.4%$173.31M$80K-0.993News CoverageGap UpHigh Trading VolumeVYGRVoyager Therapeutics3.9573 of 5 stars$3.11+5.1%$13.39+330.5%-57.6%$172.10M$66.96M-2.13100News CoverageHigh Trading VolumeFDMT4D Molecular Therapeutics2.3078 of 5 stars$3.71-3.4%$29.56+696.6%-80.4%$171.88M$40K-1.17120News CoverageAnalyst ForecastPBYIPuma Biotechnology3.9489 of 5 stars$3.43+3.0%$7.00+104.1%+17.5%$170.23M$230.50M4.45200IPHAInnate Pharma2.5465 of 5 stars$1.82-1.9%$11.00+506.1%-15.3%$167.31M$21.77M0.00220Positive NewsGap DownDMACDiaMedica Therapeutics0.9035 of 5 stars$3.90+1.6%$8.00+105.1%+26.3%$167.23MN/A-6.0920 Related Companies and Tools Related Companies ORIC Alternatives DRUG Alternatives CTMX Alternatives OGI Alternatives PROK Alternatives VYGR Alternatives FDMT Alternatives PBYI Alternatives IPHA Alternatives DMAC Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:ATRA) was last updated on 7/5/2025 by MarketBeat.com Staff From Our PartnersPresidential Bombshell: $150T Resource to Be Released as soon as this Summer?Something extraordinary is happening in Washington. For the first time in over a century, a sitting Preside...Paradigm Press | SponsoredTrump’s New Order Could Boost Social Security Benefits by 400%If you collect—or plan to collect—Social Security, you need to see this. A new initiative tied to President...InvestorPlace | SponsoredWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | SponsoredElon’s NEXT Big IPO?Cancel your internet TODAY!? Take your latest internet bill and light it on fire… then count the seconds it...Banyan Hill Publishing | SponsoredA grave, grave error.Famed financial analyst, Porter Stansberry, calls this technology “The Final Frontier” because it holds the ke...Porter & Company | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | Sponsored3..2..1.. AI 2.0 ignition (don’t sleep on this)I just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | SponsoredBuffett’s $325 Billion Cash Problem — Solved by Gold?A bombshell announcement is just weeks away — and it could send shockwaves through the gold market. Most inves...Golden Portfolio | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Atara Biotherapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Atara Biotherapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free ATRA Stock Alerts